Grants per year
Personal profile
Research Interests
Dr. Hussain's research is focused on the development of novel therapeutics integrating scientific advances into clinical trials in prostate and bladder cancer.
Dr. Hussain is a GU medical oncologist with a focus on prostate and bladder cancer.
Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine. She is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology particularly prostate and bladder cancer. Her clinical research has contributed to impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer. Prior to joining the Northwestern University faculty Dr. Hussain has served in many scientific and leadership roles at the University of Michigan Comprehensive Cancer Center including Associate Director for Clinical Research and Co-Leader of the Prostate Cancer/Genitourinary Oncology Program, as well as the Associate Chief for Clinical Research in the Division of Hematology/Oncology. At the national level Dr. Hussain has served in a variety of scientific leadership roles, including the Co-Chair of the SWOG Prostate Cancer Subcommittee (1994-2012), member (2009-2014) and Chair (2013-2014) of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program, and was a member (2004-2008) and Chair (2007-2008) of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. Dr. Hussain was a member of the NCI-Cancer Biomarker Study Section and the NCI’s Prostate cancer task force. She currently serves as an EAB member for several NCI-designated cancer centers and the UCLA Prostate Cancer SPORE. Since joining the American Society of Clinical Oncology in 1990, Dr. Hussain has served on numerous committees and boards, including the Scientific Program, Cancer Education, International Affairs, and Cancer Communications committees. In addition, she chaired the Cancer Education Committee (2008-2009), the Genitourinary Cancers Symposium Program Committee (2010-2011) and the Genitourinary Cancers Symposium Steering Committee (2013-2014) and was Associate Editor for Cancer.Net. She currently serves on the Clinical Practice Guidelines Committee and is an elected member of the ASCO Board of Directors. Dr. Hussain is the author of more than 240 scholarly articles and book chapters. She serves/has served on the editorial boards for several national and international specialty publications. She has been invited to give hundreds of lectures on her work in the United States and many countries around the world. Dr. Hussain has received many honors, including the University of Michigan Comprehensive Cancer Center Leadership Award (2007), the University of Michigan Medical School League Of Research Excellence (2011), and the 2012 Clinical & Health Services Research Award. She was elected as a Fellow of ASCO (2010). She has been named for many years in America’s Top Doctors” and “America´s Top Doctors for Cancer. In 2015 she was named one of OncLive’s Giants of Cancer Care and in 2017 she was named Castle Connolly Exceptional Women in Medicine.
Training Experience
1983 | Internship, Wayne State University |
1986 | Residency, Wayne State University School of Medicine, Detroit, Michigan |
1989 | Fellowship, Wayne State University School of Medicine, Detroit, Michigan |
Education/Academic qualification
MBChB, Baghdad University College of Medicine, Baghdad, Iraq
… → 1980
Fingerprint
- 3 Similar Profiles
Network
Grants
-
Prot #ARV-110-mCRPC-101: A Phase 1/2, Open-label, Dose Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients with Metastatic Castration-resistant Prostate Cancer
Novella Clinical, LLC, Arvinas, Inc.
7/31/20 → 7/31/23
Project: Research project
-
SWOG NCORP Accrual Site
Oregon Health and Science University, National Cancer Institute
8/1/19 → 7/31/25
Project: Research project
-
EDDOP Leadership: Early Drug Development Opportunity Program
8/10/18 → 7/31/23
Project: Research project
-
The Robert H. Lurie Comprehensive Cancer Center
Agulnik, M., Awatramani, R., Cella, D., Chakravarti, D., Chandel, N., Crispino, J. D., Cristofanilli, M., Eklund, E. A., Frankfurt, O., Horbinski, C. M., Horvath, C. M., Hussain, M., James, C. D., Kelleher, N. L., Khan, S. A., LaBonne, C., Larson, A. C., Matei, D. E., Mrksich, M., Munshi, H. G., Murphy, A. B., Penedo, F. J., Perlman, H. R., Peter, M. E., Rademaker, A. W., Rappoport, J. Z., Scheidt, K. A., Simon, M. A., Sosman, J. A., Spring, B., Wei, J., Weiss, E. L., Woloschak, G. E., Obeng, R., Hitsman, B. L., Butt, Z., Arvanitis, C., Wignall, S., Shilatifard, A., Kocherginsky, M., Rini, C., Bonini, M., Kumthekar, P. U., Mondragon, A., Benson III, A. B., Gordon, L. I., Green, K. J., Rosenzweig, A. C., Meade, T. J., Platanias, L. C., Carthew, R. W., Backman, V. & Hahn, E. A.
8/10/18 → 7/31/23
Project: Research project
-
Administrative Supplements to Existing NIH Grants and Cooperative Agreements
8/10/18 → 7/31/23
Project: Research project
Research Output
-
Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2–ERG fusions
Chalmers, Z. R., Burns, M. C., Ebot, E. M., Frampton, G. M., Ross, J. S., Hussain, M. H. A. & Abdulkadir, S. A., 2021, (Accepted/In press) In: Prostate Cancer and Prostatic Diseases.Research output: Contribution to journal › Article › peer-review
Open Access -
Newly diagnosed high-risk prostate cancer in an era of rapidly evolving new imaging: How do we treat?
Hussain, M., Lin, D., Saad, F., Vapiwala, N., Chapin, B. F., Sandler, H., Evans, C. P., Carducci, M. A. & Sachdev, S., Jan 1 2021, In: Journal of Clinical Oncology. 39, 1, p. 13-16 4 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary
Hofmann, M. R., Hussain, M., Dehm, S. M., Beltran, H., Wyatt, A. W., Halabi, S., Sweeney, C., Scher, H. I., Ryan, C. J., Feng, F. Y., Attard, G., Klein, E., Miyahira, A. K., Soule, H. R. & Sharifi, N., 2021, (Accepted/In press) In: Urology.Research output: Contribution to journal › Review article › peer-review
Open Access -
Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024
de Bono, J., Hussain, M. & Kang, J., Mar 2021, In: European urology. 79, 3, p. e83-e84Research output: Contribution to journal › Letter › peer-review
-
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors
Isakoff, S. J., Tabernero, J., Molife, L. R., Soria, J. C., Cervantes, A., Vogelzang, N. J., Patel, M. R., Hussain, M., Baron, A., Argilés, G., Conkling, P. R., Sampath, D., Maslyar, D., Patel, P., Chan, W., Gendreau, S., Musib, L., Xu, N., Ma, H., Lin, K. & 1 others, , May 2020, In: Annals of Oncology. 31, 5, p. 626-633 8 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations